AU Patent

AU2010256366B2 — Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders

Assigned to Veroscience LLC · Expires 2014-08-21 · 12y expired

What this patent protects

The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

USPTO Abstract

The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010256366B2
Jurisdiction
AU
Classification
—
Expires
2014-08-21
Drug substance claim
No
Drug product claim
No
Assignee
Veroscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.